RepRegen™ receives visit from His Royal Highness, Prince Andrew, Duke of York

LONDON--(BUSINESS WIRE)--RepRegen, the ‘smart biomaterials’ company, welcomed His Royal Highness, Prince Andrew, Duke of York to its headquarters earlier today, where he met with CEO Mr. Ian Brown and CSO Professor Molly Stevens and learned about RepRegen’s commercialization plans for StronBone in Europe and the U.S.

“The attention of Prince Andrew underscores the considerable progress RepRegen is making toward designing superior orthopaedic products that may enhance patient outcomes”

StronBone bioactive glass with Strontium is the first product that is being commercialized from RepRegen’s repair and regeneration platform of ‘smart’ biomaterials for bone and other (hard) tissue. Recently, RepRegen received CE Marking Approval for StronBone and also submitted StronBone to the U.S. FDA for 510(k) clearance. RepRegen has discovered that the addition of Strontium ‘turbocharges’ the bioactivity of bioceramic technology; this major materials science discovery enables development of enhanced products to repair and regenerate bone and other (hard) tissue.

“We are very proud to be able to show Prince Andrew the substantial progress that RepRegen is making toward commercialization of its advanced biomaterials. These one-of-a-kind biomaterials make possible a new paradigm in designing premium products for tissue repair and regeneration by supporting and enhancing natural cellular growth and tissue regeneration in vivo,” said Mr. Ian Brown, RepRegen’s CEO.

“The attention of Prince Andrew underscores the considerable progress RepRegen is making toward designing superior orthopaedic products that may enhance patient outcomes,” added Chairman Dr. Stephen Rietiker.

About RepRegen™ Ltd

RepRegen is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in vivo. The first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. A spin-out company from Imperial College London, RepRegen is headquartered within the Imperial College Incubator.

RepRegen’s first product is StronBone^TM bone graft substitute bioactive glass with Strontium. StronBone and other products in the “hard tissue repair and regeneration” range are for orthopaedic (trauma and spine) and craniomaxillofacial applications.

RepRegen develops products to repair and restore tissue better and faster. The company’s Smart Biomaterials are designed both to support and to improve cellular growth in vivo. The materials comprise innovations in bioactive ceramics or biomimetic polymer scaffolds. One of the most remarkable RepRegen innovations is the use of Strontium which gives the formation of bone tissue an additional boost. Both product lines have significant competitive advantages, on the one hand, by enhancing cellular growth through topography of scaffolds and on the other hand, by the use of specially selected materials.

RepRegen’s Chairman and CEO each have considerable experience in starting, building and growing medtech companies. Dr. Rietiker, MD, is Chairman of RepRegen, Chairman of the Switzerland-based investment platform AurigaVision AG and Senior Advisor to Brown Brothers Harriman. Steve was formerly CEO of Sulzer Medica/Centerpulse. Mr. Ian Brown MBA, CEO of RepRegen, has 25 years of international industry experience, including Chromogenix (Sweden), Instrumentation Laboratory (Italy) and Cordlife (Singapore and Australia) and he is an alumnus of INSEAD (France), Europe’s leading business school. RepRegen’s CSO is Professor Molly Stevens. Prof. Stevens is Professor of Biomedical Materials and Regenerative Medicine and Research Director for Biomedical Material Sciences at the Institute of Biomedical Engineering, Imperial College London. Molly joined Imperial College London in 2004 after spending several years as a Postdoctoral Associate in the Chemical Engineering Department at the Massachusetts Institute of Technology (MIT).

Note: In the EU, StronBone Bone Graft Substitute is a medical device product which has CE Marking approval. In the USA, StronBone Bone Graft Substitute is a medical device product that has not yet been cleared by the FDA and can therefore only be used for investigational use.